Přejít k hlavnímu obsahu
Header image

PerMed: T2BA Consortium meeting + T2BA Scientific Board meeting (NCC Council) photo report

From June 17-18, 2024, IMTM held the PERMED: T2BA Consortium meeting and T2BA Scientific Board meeting (NCC Council). 

The aim of PERMED T2BA is to develop both personalized diagnostic methods and drugs which would help specific groups of patients. The project is addressing one main research topic - Biomedicine and the secondary one - ICT in the digital age (Al, virtual reality, big data), both topics are part of the programme and call.


Monday 17th June

12:15-12:30   INTRODUCTORY INFORMATION – Hajdúch 
12:30-13:00   Hajdúch (DP 11) Biomarkers and molecular diagnostics for personalized medicine 
13:00-13:30   Kudová (DP 6) - Study of functional and behavioral consequences of disease-associated mutations in the NMDA receptor and potential rescue pharmacology 
13:30-14:00   Janeba (DP7) Purine nucleoside phosphorylase inhibitors for treatment of T-cell leukemia 
14:00-14:15 BREAK 
14:15-14:45   Tichý (DP 3) Novel nucleoside analogues as potent anticancer drugs 
14:45-15:15   Maloy Řezáčová (DP4) – Theranostic applications of cancer specific carbonic anhydrases 
15:15-15:45   Vrábel (DP 5) Development of chimeric antigen receptor modified immune cells for cancer immunotherapy 
15:45-16:15   Nencka (DP 9) Novel (multi)targeted ligands of nuclear receptors for the therapy of the metabolic diseases 
16:30-17:00   BOARD MEETING onsite and/or online (Decristoforo, Fusek, Hajdúch, Hauser, Martásek, Normanton, Perlík) 

ROOM 2.48 
12:30-14:00   and/or ADMINISTRATION MEETING (onsite and/or online) 
14:15-15:45   Project managers of partners 


Tuesday 18th June: 

09:00-9:30   Petřík (DP 10) - Targeted molecular imaging of infection and cancer disorders 
9:30-10:00   Maletínská (DP 8) Interplay between anorexigenic and orexigenic peptides in Alzheimer’s-like pathology 
10:00-10:30   Martásek (DP 13) - Biomedical prospecting of a life pigment: metabolic basis of inherited heme deficiency disorders 
10:30-10:45 BREAK 
10:45-11:15   Janovská (DP 12) – Casein kinase inhibitors for treatment of human cancers 
11:15-11:45   Macek (DP 2) - Artificial intelligence, telemedicine and machine learning system for clinical applications 
11:45-12:15   Brož (DP 1) - Development of informatic solutions enabling digitalization, interpretation and management of human genome data in clinical practice 





National Centers of Competence 
Personalised Medicine: From Translational Research into Biomedical Applications 
PERMED: T2BA (TN02000109) 


Photo: Denisa Pavelková